According to RaySearch’s articles of association, owners of Class A shares have the right to have such shares converted to Class B shares. Conversion reduces the total number of votes in the company.
On June 29 RaySerach issued a press release regarding conversion of shares in June. The information in the press release was correct but it should have been issued on the last day of trading, June 30, and not on June 29 which was the case. To ensure correct financial reporting, the same information is therefore published again as stated below. No conversion of shares has occurred in July.
In June, at the request of Bengt Lind, 1,061,577 Class A shares were converted to Class B shares.
The total number of votes in the company thereafter amounts to 136,202,292.
The total number of registered shares in the company amounts to 34,282,773, of which 11,324,391 are Class A shares and 22,958,282 are Class B shares.
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch’s products are mainly sold through license agreements with leading partners such as Philips, Nucletron, IBA Dosimetry, Varian, TomoTherapy and Siemens. To date, 15 products have been launched through partners and RaySearch’s software is used at some 1,800 clinics in more than 30 countries. In addition, RaySearch offers the proprietary treatment planning system RayStation® directly to clinics. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.
For more information about RaySearch, visit www.raysearchlabs.com.
For further information, contact:
Anders Martin-Löf, CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-545 061 30